Valuation: Norda ASA

Market Cap 513M 53.57M 47.87M 44.66M 40.57M 76.4M 5.18B 76.97M 537M 210M 2.64B 201M 197M 8.47B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 27.6M 24.66M 23.01M 20.9M 39.36M 2.67B 39.65M 276M 108M 1.36B 104M 101M 4.36B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day-1.05%
1 week-1.05%
Current month-1.05%
3 months-1.50%
Current year-14.90%
1 week 85.1
Extreme 85.1
85.1
1 month 85.1
Extreme 85.1
86.4
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%-1.05%+5.06%+107.56% 45.59M
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.81%-15.66%+3.29%+51.99% 58.7B
-2.15%+0.68%+3.60%+31.56% 48.36B
-8.88%-10.95%+283.43%+619.89% 43.05B
-1.79%-2.85%+26.26%+26.93% 42.48B
-6.12%-4.45%-2.36%+98.39% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-2.88%-4.78%-13.23%-15.63% 23.93B
-4.03%-10.23%-39.76%+297.72% 22.22B
Average -4.53%-1.94%+32.01%+135.90% 38.61B
Weighted average by Cap. -5.47%-1.54%+41.45%+131.94%

Financials

2023 2024
Net sales 86.92M 9.07M 8.11M 7.56M 6.87M 12.94M 878M 13.04M 90.9M 35.51M 446M 34.07M 33.33M 1.44B 372M 38.82M 34.69M 32.36M 29.39M 55.36M 3.76B 55.77M 389M 152M 1.91B 146M 143M 6.14B
Net income 31.17M 3.25M 2.91M 2.71M 2.46M 4.64M 315M 4.68M 32.6M 12.74M 160M 12.22M 11.95M 515M 126M 13.15M 11.75M 10.96M 9.96M 18.75M 1.27B 18.89M 132M 51.46M 647M 49.36M 48.3M 2.08B
Net Debt -311M -32.49M -29.03M -27.09M -24.6M -46.34M -3.14B -46.68M -326M -127M -1.6B -122M -119M -5.14B -249M -25.98M -23.21M -21.65M -19.67M -37.04M -2.51B -37.32M -260M -102M -1.28B -97.52M -95.41M -4.11B
Projected Income Statement - Annual - Norda ASA
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. NORD Stock